Government caps trade margins on cancer drugs at 30%, cutting prices up to 70%
By United One News · AI-generated summary of 6 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
India will limit trade margins on most cancer drugs to 30%, potentially lowering prices by up to 70% and saving patients about ₹2,500 crore annually.
- The cap applies to branded and generic, domestic and imported, patented and non‑patented anti‑cancer medicines.
- Prices could drop by up to 70% for affected drugs.
- The measure is expected to generate annual savings of roughly ₹2,500 crore for patients.
Covered by 6 outlets across the spectrum: 17% left, 66% center, 17% right.
How each side framed it
Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP
Cancer drugs to get cheaper by up to 70% as govt fixes trade margin at 30%
Cancer drug prices may fall as government plans 30% trade margin cap
Timeline
First reported by DNA India on ; 6 articles from 6 outlets so far.
Who is covering this story
- Left-leaning (1): The Hindu
- Center (4): DNA India, The Hindu BusinessLine, Deccan Herald, Tribune India
- Right-leaning (1): Times of India
Sources
- Cancer drugs to get cheaper by up to 70% as govt fixes trade margin at 30% — DNA India (center) ·
- Cancer drug prices likely to fall as govt caps trade margins at 30% — The Hindu BusinessLine (center) ·
- Govt to cap trade margins at 30% of MRP for anti-cancer drugs — Deccan Herald (center) ·
- Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP — The Hindu (left-leaning) ·
- Centre to cap trade margins at 30% for non-scheduled anti-cancer drugs — Tribune India (center) ·
- Cancer drug prices may fall as government plans 30% trade margin cap — Times of India (right-leaning) ·